JP6501524B2 - Ｐｓｍａ上昇により致死性前立腺癌が同定される - Google Patents

Ｐｓｍａ上昇により致死性前立腺癌が同定される Download PDF

Info

Publication number
JP6501524B2
JP6501524B2 JP2014558737A JP2014558737A JP6501524B2 JP 6501524 B2 JP6501524 B2 JP 6501524B2 JP 2014558737 A JP2014558737 A JP 2014558737A JP 2014558737 A JP2014558737 A JP 2014558737A JP 6501524 B2 JP6501524 B2 JP 6501524B2
Authority
JP
Japan
Prior art keywords
psma
imaging
agent
expression
pet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014558737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513083A5 (https=
JP2015513083A (ja
Inventor
バンダー，ニール・エイチ
Original Assignee
コーネル ユニヴァーシティー
コーネル ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, コーネル ユニヴァーシティー filed Critical コーネル ユニヴァーシティー
Publication of JP2015513083A publication Critical patent/JP2015513083A/ja
Publication of JP2015513083A5 publication Critical patent/JP2015513083A5/ja
Application granted granted Critical
Publication of JP6501524B2 publication Critical patent/JP6501524B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
JP2014558737A 2012-02-24 2013-02-22 Ｐｓｍａ上昇により致死性前立腺癌が同定される Expired - Fee Related JP6501524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602900P 2012-02-24 2012-02-24
US61/602,900 2012-02-24
PCT/US2013/000045 WO2013126147A2 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019050913A Division JP2019144254A (ja) 2012-02-24 2019-03-19 Ｐｓｍａ上昇により致死性前立腺癌が同定される

Publications (3)

Publication Number Publication Date
JP2015513083A JP2015513083A (ja) 2015-04-30
JP2015513083A5 JP2015513083A5 (https=) 2016-03-31
JP6501524B2 true JP6501524B2 (ja) 2019-04-17

Family

ID=49003541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014558737A Expired - Fee Related JP6501524B2 (ja) 2012-02-24 2013-02-22 Ｐｓｍａ上昇により致死性前立腺癌が同定される
JP2019050913A Pending JP2019144254A (ja) 2012-02-24 2019-03-19 Ｐｓｍａ上昇により致死性前立腺癌が同定される

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019050913A Pending JP2019144254A (ja) 2012-02-24 2019-03-19 Ｐｓｍａ上昇により致死性前立腺癌が同定される

Country Status (6)

Country Link
US (2) US20130225541A1 (https=)
EP (2) EP2817629A4 (https=)
JP (2) JP6501524B2 (https=)
CA (1) CA2865282A1 (https=)
HK (1) HK1205788A1 (https=)
WO (1) WO2013126147A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130177A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
AU2017348111B2 (en) * 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
EP4597424A3 (en) 2019-01-07 2025-10-29 Exini Diagnostics AB Systems and methods for platform agnostic whole body image segmentation
BR112021021011A2 (pt) 2019-04-24 2021-12-14 Exini Diagnostics Ab Sistemas e métodos para análise automatizada e interativa de imagens de varredura óssea para detecção de metástases
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
BR112022019335A2 (pt) 2020-03-26 2022-11-29 Marigdalia Kaleth Ramirez Fort Método para determinar uma quantidade de energia a ser entregue para provocar um efeito final em uma entidade invasiva-alvo de um alvo em um hospedeiro, método para fornecer terapia a um alvo com o uso de um dispositivo inteligente, método para monitorar um paciente exposto a um carcinógeno conhecido em um evento de exposição, método para tratar adaptativamente um volume de células com irradiação eletromagnética, método para medir a dose absorvida de energia entregue por meio de um alvo dentro de um volume de células, método para permitir regulação ascendente de depravação de androgênio, método para otimizar a dose absorvida de irradiação eletromagnética entregue por meio de um alvo dentro de um volume de células, sistema de terapia para um apêndice de paciente e sistema de terapia para uma cavidade de paciente
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
CA3231578A1 (en) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE337011T1 (de) * 2001-02-07 2006-09-15 Beth Israel Hospital Modifizierte psma-liganden und deren verwendung
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
ATE408712T1 (de) * 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2005021709A2 (en) * 2003-05-29 2005-03-10 Diadexus, Inc. Cln101 antibodies
JP2010507645A (ja) * 2006-10-25 2010-03-11 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 前立腺癌を検出するための造影剤
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
WO2010107909A2 (en) * 2009-03-17 2010-09-23 The Johns Hopkins University Methods and compositions for the detection of cancer

Also Published As

Publication number Publication date
CA2865282A1 (en) 2013-08-29
EP2817629A2 (en) 2014-12-31
WO2013126147A3 (en) 2014-12-24
WO2013126147A2 (en) 2013-08-29
US20130225541A1 (en) 2013-08-29
JP2019144254A (ja) 2019-08-29
US20180088120A1 (en) 2018-03-29
JP2015513083A (ja) 2015-04-30
EP2817629A4 (en) 2016-01-13
EP3064945A1 (en) 2016-09-07
HK1205788A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
JP6501524B2 (ja) Ｐｓｍａ上昇により致死性前立腺癌が同定される
Donato et al. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology
Baas et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Créhange et al. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm
Kunikowska et al. [68 Ga] Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma
Sadeghi-Naini et al. Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture
HK1223847A1 (zh) 使用spect/ct分析进行癌症分期的方法
Khandani et al. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development
Jinghua et al. Clinical prospective study of Gallium 68 (68Ga)–labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma
Serban et al. Local recurrence management of extremity soft tissue sarcoma
Kwon et al. Prevalence and clinical significance of incidental 18F-fluoro-2-deoxyglucose uptake in prostate
Wang et al. Application of near-infrared fluorescence imaging in the accurate assessment of surgical margins during breast-conserving surgery
Abdel-Moety et al. SQSTM1 expression in hepatocellular carcinoma and relation to tumor recurrence after radiofrequency ablation
Brassell et al. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer
Huang et al. HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response
Dong et al. 18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer
Murata et al. SUVmax-based parameters of FDG-PET/CT reliably predict pathologic complete response after preoperative hyperthermo-chemoradiotherapy in rectal cancer
Nadebaum et al. Oligometastatic renal cell carcinoma with sarcomatoid differentiation demonstrating variable imaging phenotypes on 68Ga-PSMA and 18F-FDG PET/CT: A case report and review of the literature
Houvast et al. Prediction of biomarker expression on primary pancreatic ductal adenocarcinoma tissues using Fine-Needle biopsies: paving the way for a Patient-Tailored molecular imaging approach
Sengoz et al. Confirmation of PSMA expression measured on [68Ga] Ga-PSMA PET/CT by immunohistochemistry in prostate adenocarcinoma
Jiang et al. Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2
Kang et al. Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression
Safarian et al. The role of non-FDG agents in PET imaging of bladder cancer
Mouraviev et al. Use of 111In-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland
Kawamoto Therapy Response Imaging in Gastrointestinal Malignancy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190319

R150 Certificate of patent or registration of utility model

Ref document number: 6501524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees